A comprehensive study using multiple experimental models validated the potential blood pressure reduction effect of rivaroxaban

Current Molecular Pharmacology · Published 2026-06-01 · DOI 10.1016/j.cmp.2026.06.001

Free full text

Authors (12)

Hongyu Kuang, Kexin Li, Hong Yang, Ke Yang, Zhirou Zhang, Jie Zhu, Jia Wei, Pei Pan, Jinghong Chen, Yihan Chen, Chang Qi, Huaan Du

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Kuang, H., Li, K., Yang, H., et al. (2026). A comprehensive study using multiple experimental models validated the potential blood pressure reduction effect of rivaroxaban. Current Molecular Pharmacology. https://doi.org/10.1016/j.cmp.2026.06.001

Related articles

• Targeting fPRDM16 to restore collagen phagocytosis: A mechanism to counteract the persistent fibrosis in aging lungs · Current Molecular Pharmacology · 2026 · Same journal
• Chrysin: A Potential Antiandrogen Ligand to Mutated Androgen Receptors in Prostate Cancer · Current Molecular Pharmacology · 2025 · Same journal
• Protective Effect of Platycodin D on Allergic Rhinitis in Mice through DPP4/JAK2/STAT3 Pathway Inhibition · Current Molecular Pharmacology · 2025 · Same journal
• Neuroprotective Potential of Tanshinone-IIA in Mitigating Propionic Acidinduced Experimental Autism-like Behavioral and Neurochemical Alterations: Insights into c-JNK and p38MAPK Pathways · Current Molecular Pharmacology · 2024 · Same journal
• Regulatory Mechanisms of STAT3 in GBM and its Impact on TMZ Resistance · Current Molecular Pharmacology · 2025 · Same journal
• Optimization of bioinformatics-designed thiazolide derivatives as SARS-CoV-2 nucleocapsid protein inhibitors · Current Molecular Pharmacology · 2026 · Same journal
• Doxazosin Attenuates Development of Testosterone Propionate-induced Prostate Growth by regulating TGF-β/Smad Signaling Pathway, Prostate-specific Antigen Expression and Reversing Epithelial-Mesenchymal Transition in Mice and Stroma Cells · Current Molecular Pharmacology · 2025 · Same journal
• Intra-tumor DKK1 and CALML5 heterogeneity as a novel biomarker for prognosis and immunotherapy response in head and neck squamous cell carcinoma · Current Molecular Pharmacology · 2025 · Same journal
• IGFBP1 is a potential monitoring biomarker of disease activity in elderly patients with inflammatory bowel disease · Current Molecular Pharmacology · 2026 · Same journal
• Cilia Plays a Pivotal Role in the Hypersecretion of Airway Mucus in Mice · Current Molecular Pharmacology · 2025 · Same journal